Search
for
Sort by
Research 61–90 of 1000+
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- New drugs under investigation for the treatment of alopecias
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- What is behind the ‘swarm of bees’ in alopecia areata
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Janus kinase inhibitors in dermatology: A systematic review
- Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Janus Kinase Inhibitors for Alopecia Areata
- Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors
- Single‐cell transcriptomics reveals a senescence‐associated IL ‐6/ CCR6 axis driving radiodermatitis
- Emerging role of baricitinib in dermatology practice: All we need to know!
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- A review of Janus kinase inhibitor use in scarring alopecia
- Biologics in the management of childhood atopic dermatitis
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials